Genitope Corporation (Nasdaq: GTOP) today announced that it will be presenting at the RBC Capital Markets Healthcare Conference being held at the Westin New York at Times Square Hotel in New York City on Thursday, December 14, 2006.

Dan W. Denney, Jr., Ph.D., chairman of the board and chief executive officer of Genitope Corporation will participate on the New Antibody Technology panel scheduled for Thursday, December 14th at 1:00 pm.

A live audio webcast of the panel discussion will be accessible for 30 days through the company's website at http://www.genitope.com.

About Genitope Corporation

Genitope Corporation (Fremont, Calif.) is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation's lead product candidate, MyVax® personalized immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells. For more information on the company, please log on to http://www.genitope.com.